Rosiptor - Aquinox Pharmaceuticals

Drug Profile

Rosiptor - Aquinox Pharmaceuticals

Alternative Names: AQX 1125

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquinox Pharmaceuticals
  • Class Androstanes; Anti-inflammatories; Immunotherapies; Indenes; Small molecules
  • Mechanism of Action Inositol-1,4,5-trisphosphate 5-phosphatase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Interstitial cystitis
  • Phase II Allergic asthma
  • Discontinued Atopic dermatitis; Chronic obstructive pulmonary disease; Haematological disorders; Hypersensitivity; Immunological disorders; Inflammation; Irritable bowel syndrome; Pulmonary fibrosis

Most Recent Events

  • 12 Mar 2018 Aquinox Pharmaceuticals completes enrolment in the phase III LEADERSHIP 301 trial in Interstitial cystitis in USA, Denmark, Netherlands, Hungary, Czech Republic, United Kingdom, Canada, Latvia, Romania, Spain, Belgium and Poland
  • 12 Mar 2018 Aquinox Pharmaceuticals plans a phase II trial for Prostatitis (Chronic Prostatitis/Chronic Pelvic Pain Syndrome) in USA and Canada in the second quarter of 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top